Sponsors and Sites: How HCRF Expands Clinical Trial Diversity

September 11, 2026

Sponsors and Sites: How HCRF Expands Clinical Trial Diversity

Coordinator discussing clinical trial enrollment with patient

Clinical trial diversity means enrolling participants whose race, ethnicity, age, sex, and health background actually reflect the people who will use the treatment once it’s approved. It matters because drugs and devices tested mostly on one type of body can behave differently, sometimes dangerously, in everyone else. Closing that gap requires action from sponsors, research sites, regulators, and the communities who’ve been left out for decades.

TL;DR:

Increasing trial diversity requires deliberate criteria review and expanding site locations to include rural and underserved communities.

Built-in monitoring of demographics against disease prevalence and real-time dashboards is essential for measuring progress effectively.

Favoring decentralized visit options, translating materials, and reimbursing costs remove key barriers to participation for underrepresented groups.

Regulatory efforts like FDA Diversity Action Plans need stronger enforcement and intersectional tracking to drive real change.

Nonprofit organizations and community engagement are critical for education, navigation, and building trust to improve enrollment equity.

Hcrfwingstocure

Support More Inclusive Cancer Research

HCRF supports out of the box cancer research at Northwestern's Lurie Cancer Center, helping advance research that serves more patients.

Learn about HCRF

Why Diversity in Clinical Trials Protects Safety, Efficacy, and Equity
What Keeps Underrepresented Populations Out of Clinical Research
FDA Guidance, Diversity Action Plans, and the Policy Gaps Sponsors Face
How Sponsors and Sites Can Actually Increase Enrollment Diversity
Tracking Progress: The Metrics That Actually Show Whether Diversity Improved
How Nonprofits and Patient Groups Like HCRF Expand Access and Trust
Embedding Equity Across the Research Lifecycle
How HCRF Helps Patients and Funders Accelerate Equitable Research
Key Resources for Understanding Clinical Trial Diversity
Sources

Why Diversity in Clinical Trials Protects Safety, Efficacy, and Equity

A treatment doesn’t work the same way in every body. Genetics, metabolism, body composition, and even diet shift how a drug is absorbed, processed, and cleared. Pharmacokinetic differences tied to age, sex, and ancestry can change how fast a drug breaks down or how strongly it binds to its target, which means a dose calibrated on a narrow study population can be too strong, too weak, or simply the wrong fit for someone left out of the research.

When trials skip broad enrollment, the consequences show up years later. A drug label might miss a safety signal that only appears in a population barely represented during testing. Dosing guidance built on a homogenous group can lead to real-world side effects, treatment failures, or missed warnings for people the trial never studied. That’s not a hypothetical risk. Racial and ethnic minorities make up nearly [40% of the U.S. population but remain significantly underrepresented in clinical research](https://cancer.umn.edu/mncctn/news/minority-health-month-why-diversity-necessary-clinical-trials), a gap wide enough to distort what “safe and effective” even means once a product reaches the general public.

The gap has a price tag. Economic analyses from the Schaeffer Center at USC estimate that failing to include diverse populations in trials costs substantial amounts, driven by widened health disparities and treatments that underperform for the patients who need them most.

Underrepresentation isn’t only an ethical problem. It’s a data quality problem. A trial population that doesn’t mirror the intended-use population produces results that are technically valid but practically incomplete. Regulators, physicians, and patients end up making decisions with a partial picture, and the people paying for that gap are usually the ones who were already hardest to reach. Improving representation strengthens the evidence itself, which is exactly why treating diversity in clinical trials as core science, not an add-on requirement, tends to produce better medicine.

What Keeps Underrepresented Populations Out of Clinical Research

Most barriers to trial participation aren’t about willingness. They’re about design, geography, and history stacking up against the people researchers most need to reach.

Site location. Trials cluster around major academic medical centers, often in wealthier urban or suburban areas, leaving rural communities and lower-income neighborhoods with few or no nearby sites.
Restrictive eligibility criteria. Protocols written decades ago still exclude patients with common comorbidities, prior treatments, or organ function levels that disproportionately screen out older adults and minority patients.
Historical mistrust. Past research abuses left lasting damage in some communities, and that mistrust doesn’t dissolve because a new study promises good intentions.
Language and cultural mismatches. Consent forms and study materials written only in English, without cultural context, quietly exclude entire populations before enrollment even begins.
Financial and logistic burden. Missed wages, transportation costs, childcare, and multiple clinic visits make participation impractical for people already stretched thin.

Eligibility criteria deserve particular scrutiny because they’re often inherited from prior trials without anyone asking whether the exclusions still make scientific sense. A cutoff for kidney function or a washout period from a prior medication might have been reasonable for the first phase of testing but becomes an unnecessary wall in later-stage research, one that falls hardest on populations with higher rates of the very conditions being excluded.

Pro Tip: If you’re evaluating whether a trial is worth pursuing for yourself or a loved one, ask the research coordinator directly which eligibility criteria are “hard” medical requirements versus legacy protocol language. Many teams can request a protocol amendment if a criterion is outdated.

Financial strain compounds everything else. A patient who qualifies medically and lives near a trial site can still be shut out by the cost of a hotel stay for a multi-day visit or the wages lost from a full day at the clinic. Reimbursement policies exist at many sites, but patients rarely know to ask, and understanding trial results later means little if the burden of getting there kept them from enrolling in the first place.

FDA Guidance, Diversity Action Plans, and the Policy Gaps Sponsors Face

The regulatory foundation for improving representation now rests on a specific requirement: Diversity Action Plans, or DAPs. The FDA recommends that sponsors enroll participants who reflect the population intended to use the product once approved, and its guidance pushes sponsors to broaden eligibility criteria and expand site selection rather than defaulting to the same academic centers used in prior studies.

The Food and Drug Omnibus Reform Act, known as FDORA, gave the FDA formal authority to require these plans for many late-stage trials. A DAP generally must include:

Enrollment goals broken out by race, ethnicity, age, and sex
A rationale explaining how those goals were set based on disease prevalence
Specific operational strategies the sponsor will use to reach underrepresented groups

The framework has real gaps. Commentary on FDORA’s implementation notes that enforcement mechanisms and public reporting requirements remain incomplete, which means a sponsor can submit a technically compliant DAP without facing much accountability if enrollment falls short of the stated goals. Intersectionality is another blind spot. A plan can hit its targets for race and for age separately while still failing to enroll, say, older Black women, because the categories are tracked in isolation rather than in combination.

For sponsors, the practical takeaway is straightforward: a DAP submitted late in trial design is a compliance exercise, while one built into the protocol from the start becomes a genuine recruitment strategy. Public reporting today mostly means what appears in Clinicaltrials filings and eventual FDA approval packages, which is useful but far from real-time accountability. Patients and advocates who want to track progress have to actively look, because the system doesn’t push this information forward on its own.

How Sponsors and Sites Can Actually Increase Enrollment Diversity

Improving clinical trial participant demographics takes coordinated changes across design, operations, and outreach, not a single fix bolted onto an existing protocol.

Broaden eligibility criteria deliberately. Review every exclusion against current science, not historical habit, and use enrichment strategies that identify likely responders without systematically shutting out entire demographic groups.
Choose pragmatic endpoints. Endpoints that reflect real-world outcomes, rather than narrow lab measures, make trials more relevant and often easier to run at community sites with less specialized equipment.
Map disease burden before picking sites. Compare where a condition actually concentrates against where trial sites currently exist, then expand into community clinics and regional hospitals in the gap areas.
Decentralize what can be decentralized. Telehealth visits, local lab draws, and mobile nursing reduce the travel burden that disqualifies participants before they ever get to informed consent.
Translate materials and simplify consent. Consent documents written at a lower reading level, available in multiple languages, remove one of the quieter barriers to enrollment.
Reimburse real costs. Covering transportation, parking, and lost wages signals that a sponsor understands participation has a price beyond time.
Build community advisory boards. Standing relationships with patient advocates and local health workers turn recruitment into a two-way conversation instead of a one-time ask.
Diversify the research workforce. Investigators and coordinators who reflect the communities being recruited build trust faster, and structured cultural competency training closes gaps for staff who don’t share that background.

Peer-reviewed reviews on inclusive research design list these same categories, community engagement, broadened eligibility, site diversification, and workforce training, as the core levers available to any sponsor working to embed equity into trial execution. None of these tactics work in isolation. A decentralized visit schedule means little if the consent form is still eight pages of dense legal language, and a diverse site footprint underdelivers if the staff at those sites were never trained on the specific cultural context of the patients walking through the door.

Pro Tip: Workforce diversity extends beyond the physician leading a trial. Clinical research coordinators and travel nurses often have the most patient contact, and staffing shortages in oncology can quietly limit which sites can even open enrollment. Organizations tracking oncology travel nursing staffing trends are watching a real bottleneck for site expansion.

Tracking Progress: The Metrics That Actually Show Whether Diversity Improved

Good intentions don’t move enrollment numbers. Specific, tracked metrics do.

The core dataset every trial team should monitor includes race and ethnicity, age bands, sex, geographic distribution of enrolled participants, and socioeconomic proxies like insurance status or rurality. Tracking these against the disease’s actual epidemiology, not against the general U.S. population, is what turns a diversity goal into a usable target. A cancer with higher incidence in a specific ethnic group needs an enrollment target calibrated to that incidence rate, reviewed on a set cadence rather than left static for the life of the trial.

Three reporting tools give patients, advocates, and sponsors a way to check the work:

ClinicalTrials.gov, where the public can search actively recruiting studies and review eligibility criteria before contacting a site.
FDA Drug Trials Snapshots, which summarize the demographic breakdown of participants in trials supporting a drug’s approval.
Internal sponsor dashboards, which track enrollment against DAP targets in real time, though these rarely reach public view before a trial completes.

Racial and ethnic minorities remaining underrepresented at nearly 40% of the population but a smaller share of trial rosters is the number every sponsor should be measuring against, disease by disease, trial by trial.

How Nonprofits and Patient Groups Like HCRF Expand Access and Trust

Patients rarely fail to enroll in trials because they don’t care. They fail because no one walked them through eligibility, insurance coverage, or what informed consent actually protects.

Nonprofits fill exactly that gap. Education and navigation help patients understand whether they qualify for a given trial, how insurance and out-of-pocket costs factor into participation, and what they’re actually agreeing to when they sign a consent form. Community partnerships extend that reach further, turning a single navigator into a network of trusted local voices who can answer questions before a patient ever calls a research coordinator.

The Hippocratic Cancer Research Foundation directs its work toward supporting innovative, “out of the box” cancer research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, funding studies that might otherwise struggle to find backing.

If you’re a patient or caregiver trying to move forward, a few steps help immediately:

Ask your oncology team directly whether any open trials match your diagnosis and stage.
Request a plain-language explanation of eligibility criteria before assuming you don’t qualify.
Search ClinicalTrials.gov yourself, then bring what you find to your care team for context.

Embedding Equity Across the Research Lifecycle

Equity built into a trial from the first protocol draft is cheaper, faster, and scientifically stronger than equity retrofitted after enrollment stalls. That’s not a moral aside. It’s operational reality: broadening eligibility after a trial has already screened out half its potential participants means expensive extensions and delayed answers for patients who can’t wait.

The science and the ethics point the same direction here. A trial that reflects the population it’s meant to serve produces evidence doctors can actually trust across that whole population, not just a slice of it. That takes sponsors, regulators, research sites, and community organizations moving together rather than treating diversity as one department’s job. Support your local advocacy groups, ask your care team hard questions, and push the researchers you know to make representation a design choice from day one, not a fix applied under pressure.

— HCRF

How HCRF Helps Patients and Funders Accelerate Equitable Research

This foundation exists to fund the kind of research that mainstream grant cycles often overlook, the early, unconventional ideas at the Robert H. Lurie Comprehensive Cancer Center that need initial support before they can attract larger institutional backing. Donor contributions can make a meaningful difference by targeting funding gaps in early-stage research programs.

Hcrfwingstocure

Beyond funding, HCRF supports patients directly through educational newsletters and trial navigation resources that help people understand their options without a sales pitch attached. If you’re a patient trying to find your footing after a diagnosis, or a donor who wants your contribution tied to research that’s actually trying something new, visit Hcrfwingstocure to see current funding priorities and progress reports from supported studies. You can subscribe for research updates or make a direct donation from the same page, and either step moves real research forward.

Key Resources for Understanding Clinical Trial Diversity

A short list of primary sources covers most of what patients, caregivers, and advocates need to go deeper on this topic.

FDA Diversity Action Plans guidance, the regulator’s own framework for representative enrollment and site selection.
Clinicaltrials, the two places to check enrollment demographics and search for open studies.
CTTI recommendations, organizational guidance on leadership commitment and community partnership.
National Academies action plan, the cross-sector roadmap for system-level change.

Each source approaches the problem from a different angle, regulatory, operational, and systemic, and reading them together gives a fuller picture than any single guidance document offers alone.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

News